Effects of synthetic analogues of human opiorphin on rat brain opioid receptors

Journal of Physiology and Pharmacology

Volumn 65, Issue 4, 2014, Pages 525-530

  Benyhe, Z ^a   Toth, G ^a   Wollemann, M ^a   Borsodi, A ^a   Helyes, Z ^b   Rougeot, C ^c   Benyhe, Sandor ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c INSTITUT PASTEUR   (France)

Author keywords

Met enkephalin Arg Phe; Opioid receptors; Peptidase inhibition; Radioligand binding; Rat brain membranes

Indexed keywords

ENKEPHALIN-MET, ARG(6)-PHE(7)-; GLUTAMINYL-ARGINYL-PHENYLALANYL-SERYL-ARGININE; METENKEPHALIN; OLIGOPEPTIDE; OPIATE RECEPTOR; SALIVA PROTEIN;

ANALOGS AND DERIVATIVES; ANIMAL; BINDING COMPETITION; BRAIN; CHEMISTRY; HUMAN; METABOLISM; WISTAR RAT;

ANIMALS; BINDING, COMPETITIVE; BRAIN; ENKEPHALIN, METHIONINE; HUMANS; OLIGOPEPTIDES; RATS, WISTAR; RECEPTORS, OPIOID; SALIVARY PROTEINS AND PEPTIDES;

EID: 84906859516     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Wisner A, Dufour E, Messaoudi M, et al. Human opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci USA 2006; 103: 17979-17984.
2. Toth F, Toth G, Benyhe S, Rougeot C, Wollemann M. Opiorphin highly improves the specific binding and affinity of MERF and MEGY to rat brain opioid receptors. Regul Pept 2012; 178: 71-75.
3. Benyhe S, Farkas J, Toth G, Wollemann M. Met5- enkephalin-Arg6-Phe7, an endo-genous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain. J Neurosci Res 1997; 48: 249-258.
4. Rougeot C. Opiorphin peptide derivatives as potent inhibitors of enkephalin degrading ectopeptidases. WIPO Patentscope WO: 2009; 124948.
5. Hiranuma T, Kitamura K, Taniguchi T, et al. Effects of three peptidase inhibitors, amastatin, captopril and phosphoramidon, on the hydrolysis of [Met5]-enkephalin- Arg6-Phe7 and other opioid peptides. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 276-282.
6. Hiranuma T, Kitamura K, Taniguchi T, et al. Protection against dynorphin-(1-8) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon. J Pharmacol Exp Ther 1998; 286: 863-869.
7. Song B, Marvizon JCG. Peptidases prevent mu-opioid receptor internalization in dorsal horn neurons by endogenously released opioids. J Neurosci 2003; 23: 1847-1858.
8. Bogeas A, Dufour E, Bisson J-F, Messaoudi M, Rougeot C. Structure-activity relationship study and function-based peptidomimetic design of human opiorphin with improved bioavailability property and unaltered analgesic activity. Biochem Pharmacol 2013; 2: 3. doi.org/10.4172/2167- 0501.1000122.
9. Javelot H, Messaoudi M, Garnier S, Rougeot C. Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin dependent delta-opioid pathways. J Physiol Pharmacol 2010; 61: 355-362.
10. Wollemann M, Farkas J, Toth G, Benyhe S. Characterization of [3H]Met-enkephalin-Arg6-Phe7-binding to opioid receptors in frog brain membrane preparations. J Neurochem 1994; 63: 1460-1465.
11. Pasternak GW, Wilson HA, Snyder SH. Different effects of protein modifying reagents on receptor binding of opiate agonists and antagonists. Mol Pharmacol 1975; 11: 340-351.
12. Rougeot C, Robert F, Menz L, Bisson JF, Messaoudi M. Systemically active opiorphin is a potent yet non-addictive analgesic without drug tolerance effects. J Physiol Pharmacol 2010; 61: 483-490.
13. Zurowski D, Nowak L, Machowska A, Wordliczek J, Thor PJ. Exogenous melatonin abolishes thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-GABAergic mechanism. J Physiol Pharmacol 2012; 63: 641-647.
14. Yarushkina NI, Bagaeva TR, Filaretova LP. Central corticotrophin-realising factor (CRF) may attenuate somatic pain sensitivity through involvement of glucocorticoids. J Physiol Pharmacol 2011; 62: 541-548.